Introduction: To understand the current status of and problems with drug administration support (DAS) for elderly people living in communities, we reviewed the original DAS articles for all healthcare professions.

Methods: We extracted and reviewed original articles published for 15 years from January 2000 in CiNii articles and "Igaku Chuo Zasshi". Key words were as follows: "elderly," "housebound," and "compliance management OR compliance guidance", based on the thesaurus in each database. The extracted articles were reviewed for content.

Result: In all, 34 articles were extracted. The individuals involved in DAS were family members, neighbors, home helpers, nurses, physicians, pharmacists, and devices for compliance support. Care managers were not included as support. The current status of DAS extracted by content analysis was "compliance assistance", "compliance management", and "coordination arrangement". Problems with DAS were "information sharing and inter-professional collaboration", "appropriate prescription plans for abilities and lifestyles of the elderly", and "establishing support for taking medicine".

Conclusion: We found that sharing information and inter-professional collaboration are needed to support drug administration for community-living elderly people in Japan.

Objective: The purposes of this trial were to demonstrate the feasibility and effectiveness of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients in the phase I/II prospective clinical trial. Methods: Patients with FIGO stage IB2-IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by magnetic resonance imaging were eligible for this clinical trial. The protocol therapy included 30–30.6 Gy in 15–17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of HBT and pelvic radiotherapy with a central shield up to 50–50.4 Gy in 25–28 fractions. The primary endpoint of phase II part was 2-year pelvic progression-free survival (PPFS) rate higher than historical control of 64%. Results: Between October 2015 and October 2019, 73 patients were enrolled in the initial registration and 52 patients proceeded to the secondary registration. With the median follow-up period of 37.3 months (range, 13.9–52.9 months), the 2- PPFS was 80.7% (90% confidence interval [CI]=69.7%–88%). Because the lower range of 90% CI of 2-year PPFS was 69.7%, which was higher than the historical control ICBT data of 64%, therefore, the primary endpoint of this study was met. Conclusion The effectiveness of HBT were demonstrated by a prospective clinical study. Because the dose goal determined in the protocol was lower than 85 Gy, there is room in improvement for local control. A higher dose might have been needed for tumors with poor responses.